There were 1,577 press releases posted in the last 24 hours and 413,473 in the last 365 days.

Intercept to Present at Upcoming Conference

NEW YORK, March 13, 2018 (GLOBE NEWSWIRE) --

Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced management will be participating in the following investor conference:

  • Oppenheimer 28th Annual Healthcare Conference on March 19, 2018 at 10:20 a.m. Eastern Time

Webcast information for this event will be available on the Investors page of Intercept's website at http://ir.interceptpharma.com. Archived webcasts will be available on  Intercept's website for approximately two weeks.

About Intercept
Intercept is a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, including primary biliary cholangitis (PBC), nonalcoholic steatohepatitis (NASH), primary sclerosing cholangitis (PSC) and biliary atresia. Founded in 2002 in New York, Intercept now has operations in the United States, Europe and Canada.

CONTACT: For more information about
Intercept Pharmaceuticals, please contact:

Intercept Pharmaceuticals:
Mark Vignola
+1-646-747-1000
investors@interceptpharma.com 

Media inquiries: media@interceptpharma.com 

Investor inquiries: investors@interceptpharma.com 

Primary Logo